Is Emergent Biosolutions Stock a Good Investment?
Emergent Biosolutions Investment Advice | EBS |
- Examine Emergent Biosolutions' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Emergent Biosolutions' leadership team and their track record. Good management can help Emergent Biosolutions navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Emergent Biosolutions' business and its evolving consumer preferences.
- Compare Emergent Biosolutions' performance and market position to its competitors. Analyze how Emergent Biosolutions is positioned in terms of product offerings, innovation, and market share.
- Check if Emergent Biosolutions pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Emergent Biosolutions' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Emergent Biosolutions stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Emergent Biosolutions is a good investment.
Sell | Buy |
Hold
Market Performance | Fair | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Emergent Biosolutions Stock
Researching Emergent Biosolutions' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 70.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Emergent Biosolutions has Price/Earnings To Growth (PEG) ratio of 1.55. The entity had not issued any dividends in recent years.
To determine if Emergent Biosolutions is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Emergent Biosolutions' research are outlined below:
| Emergent Biosolutions is way too risky over 90 days horizon | |
| Emergent Biosolutions appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 1.01 B. Reported Net Loss for the year was (190.6 M) with profit before taxes, overhead, and interest of 480.2 M. | |
| About 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thenewswire.com: Acquisition by Richard Lindahl of 15000 shares of Emergent Biosolutions subject to Rule 16b-3 |
Emergent Biosolutions Quarterly Liabilities And Stockholders Equity |
|
Emergent Biosolutions uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Emergent Biosolutions. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Emergent Biosolutions' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Emergent Biosolutions' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Emergent Biosolutions' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2009-11-05 | 2009-09-30 | 0.06 | 0.03 | -0.03 | 50 | ||
2009-03-05 | 2008-12-31 | 0.02 | 0.05 | 0.03 | 150 | ||
2008-05-07 | 2008-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2012-11-01 | 2012-09-30 | 0.14 | 0.18 | 0.04 | 28 | ||
2022-04-28 | 2022-03-31 | 0.13 | 0.18 | 0.05 | 38 | ||
2019-08-01 | 2019-06-30 | 0.17 | 0.12 | -0.05 | 29 | ||
2014-03-06 | 2013-12-31 | 0.36 | 0.41 | 0.05 | 13 | ||
2011-08-04 | 2011-06-30 | 0.34 | 0.39 | 0.05 | 14 |
Know Emergent Biosolutions' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Emergent Biosolutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Emergent Biosolutions backward and forwards among themselves. Emergent Biosolutions' institutional investor refers to the entity that pools money to purchase Emergent Biosolutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lsv Asset Management | 2025-06-30 | 815.6 K | Prescott Group Capital Management Llc | 2025-06-30 | 772.8 K | Millennium Management Llc | 2025-06-30 | 755.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 733.4 K | Renaissance Technologies Corp | 2025-06-30 | 689.6 K | Goldman Sachs Group Inc | 2025-06-30 | 579.4 K | Amvescap Plc. | 2025-06-30 | 565.3 K | Pacer Advisors, Inc. | 2025-06-30 | 556.7 K | Trexquant Investment Lp | 2025-06-30 | 551.4 K | Blackrock Inc | 2025-06-30 | 4.4 M | Oak Hill Advisors Lp | 2025-06-30 | 3.6 M |
Emergent Biosolutions' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 519.64 M.Market Cap |
|
Emergent Biosolutions' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.20) | |
| Return On Capital Employed | (0.09) | (0.08) | |
| Return On Assets | (0.14) | (0.13) | |
| Return On Equity | (0.39) | (0.38) |
Determining Emergent Biosolutions' profitability involves analyzing its financial statements and using various financial metrics to determine if Emergent Biosolutions is a good buy. For example, gross profit margin measures Emergent Biosolutions' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Emergent Biosolutions' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Check Emergent Biosolutions' Beneish M Score to see the likelihood of Emergent Biosolutions' management manipulating its earnings.
Evaluate Emergent Biosolutions' management efficiency
Emergent Biosolutions has Return on Asset of 0.0503 % which means that on every $100 spent on assets, it made $0.0503 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3024 %, implying that it generated $0.3024 on every 100 dollars invested. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.2 in 2025. Return On Capital Employed is likely to gain to -0.08 in 2025. At this time, Emergent Biosolutions' Non Current Assets Total are comparatively stable compared to the past year. Other Assets is likely to gain to about 7.6 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 18 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.11 | 10.27 | |
| Tangible Book Value Per Share | (0.35) | (0.34) | |
| Enterprise Value Over EBITDA | 29.02 | 30.47 | |
| Price Book Value Ratio | 1.05 | 1.00 | |
| Enterprise Value Multiple | 29.02 | 30.47 | |
| Price Fair Value | 1.05 | 1.00 | |
| Enterprise Value | 1.6 B | 1.7 B |
Emergent Biosolutions' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 2.05 |
Basic technical analysis of Emergent Stock
As of the 27th of October, Emergent Biosolutions shows the Mean Deviation of 3.33, coefficient of variation of 1056.06, and Downside Deviation of 3.28. Emergent Biosolutions technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Emergent Biosolutions variance, as well as the relationship between the value at risk and skewness to decide if Emergent Biosolutions is priced favorably, providing market reflects its regular price of 9.69 per share. Given that Emergent Biosolutions has jensen alpha of 0.4229, we urge you to verify Emergent Biosolutions's prevailing market performance to make sure the company can sustain itself at a future point.Emergent Biosolutions' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Emergent Biosolutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on Emergent Biosolutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Emergent Biosolutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Emergent Biosolutions' Outstanding Corporate Bonds
Emergent Biosolutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Emergent Biosolutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Emergent bonds can be classified according to their maturity, which is the date when Emergent Biosolutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| EMERGENT BIOSOLUTIONS INC Corp BondUS29089QAC96 | View | |
| US29082KAA34 Corp BondUS29082KAA34 | View | |
| EMERA INC 675 Corp BondUS290876AD37 | View |
Understand Emergent Biosolutions' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Emergent Biosolutions' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0696 | |||
| Market Risk Adjusted Performance | 0.3578 | |||
| Mean Deviation | 3.33 | |||
| Semi Deviation | 2.93 | |||
| Downside Deviation | 3.28 | |||
| Coefficient Of Variation | 1056.06 | |||
| Standard Deviation | 5.8 | |||
| Variance | 33.62 | |||
| Information Ratio | 0.08 | |||
| Jensen Alpha | 0.4229 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.1417 | |||
| Treynor Ratio | 0.3478 | |||
| Maximum Drawdown | 46.31 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 8.53 | |||
| Downside Variance | 10.73 | |||
| Semi Variance | 8.61 | |||
| Expected Short fall | (4.59) | |||
| Skewness | 3.81 | |||
| Kurtosis | 22.81 |
| Risk Adjusted Performance | 0.0696 | |||
| Market Risk Adjusted Performance | 0.3578 | |||
| Mean Deviation | 3.33 | |||
| Semi Deviation | 2.93 | |||
| Downside Deviation | 3.28 | |||
| Coefficient Of Variation | 1056.06 | |||
| Standard Deviation | 5.8 | |||
| Variance | 33.62 | |||
| Information Ratio | 0.08 | |||
| Jensen Alpha | 0.4229 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.1417 | |||
| Treynor Ratio | 0.3478 | |||
| Maximum Drawdown | 46.31 | |||
| Value At Risk | (5.33) | |||
| Potential Upside | 8.53 | |||
| Downside Variance | 10.73 | |||
| Semi Variance | 8.61 | |||
| Expected Short fall | (4.59) | |||
| Skewness | 3.81 | |||
| Kurtosis | 22.81 |
Consider Emergent Biosolutions' intraday indicators
Emergent Biosolutions intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Emergent Biosolutions stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Emergent Biosolutions Corporate Filings
F4 | 17th of October 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of August 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 17th of July 2025 Other Reports | ViewVerify |
Emergent Stock media impact
There is far too much social signal, news, headlines, and media speculation about Emergent Biosolutions that are available to investors today. This information is accessible both publicly - through Emergent Biosolutions' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Emergent-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Emergent Biosolutions news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Emergent Biosolutions relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Emergent Biosolutions' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Emergent Biosolutions alpha.
Emergent Biosolutions Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Emergent Biosolutions can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Emergent Biosolutions Historical Investor Sentiment
Investor biases related to Emergent Biosolutions' public news can be used to forecast risks associated with an investment in Emergent. The trend in average sentiment can be used to explain how an investor holding Emergent can time the market purely based on public headlines and social activities around Emergent Biosolutions. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Emergent Biosolutions' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Emergent Biosolutions and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Emergent Biosolutions news discussions. The higher the estimate score, the more favorable the investor's outlook on Emergent Biosolutions.
Emergent Biosolutions Maximum Pain Price Across January 16th 2026 Option Contracts
Emergent Biosolutions' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Emergent Biosolutions close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Emergent Biosolutions' options.
Emergent Biosolutions Corporate Directors
| Sue Bailey | Independent Director | Profile | |
| Jerome Hauer | Independent Director | Profile | |
| Kathryn Zoon | Independent Director | Profile | |
| Seamus Mulligan | Director | Profile |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.